Significant position of C-myc in colorectal cancer: a promising therapeutic target
Clin. transl. oncol. (Print)
; 24(12): 2295-2304, dec. 2022.
Article
in English
| IBECS
| ID: ibc-216077
Responsible library:
ES1.1
Localization: ES15.1 - BNCS
ABSTRACT
Colorectal cancer (CRC) is a malignant tumor initiating from the mucosa of the colorectum. According to the 2020 statistics from the World Health Organization, there are 10.0% CRC cases among all 19.3 million new cancers, followed by lung and breast cancer, and 9.4% CRC cases among all 9.9 million cancer deaths, ranking second. The population of CRC patients in China is large, and its incidence and mortality continue to increase each year. Despite the continuous development of surgical methods, chemotherapy, radiotherapy, targeted therapy and immunotherapy, the overall survival of CRC patients remains low. Past research has suggested that c-myc plays a pivotal role in the development of CRC. A higher expression level of c-Myc is a negative prognostic marker in CRC. However, there are few drugs targeting c-myc directly. Therefore, we focused on discovering the mechanism of c-myc in CRC to provide a reference for a better therapy choice for patients (AU)
Search on Google
Collection:
National databases
/
Spain
Database:
IBECS
Main subject:
Colorectal Neoplasms
/
Proto-Oncogene Proteins c-myc
Limits:
Humans
Country/Region as subject:
Asia
Language:
English
Journal:
Clin. transl. oncol. (Print)
Year:
2022
Document type:
Article
Institution/Affiliation country:
The First Affiliated Hospital of Chongqing Medical University,/China